June 12, 2017August 24, 2022
Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
June 7, 2017June 7, 2017
Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
June 5, 2017June 5, 2017
EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
June 2, 2017June 2, 2017
DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
May 23, 2017May 23, 2017
Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more

April 7, 2017April 7, 2017

Half of RA Patients Stop Long-Term Anti-TNF Treatment; Decreased Effectiveness is Main Reason

Rheumatoid arthritis (RA) patients discontinue long treatments with anti-TNF therapies mainly because the drug therapies lose effectiveness, according to a new study. The results, which included data from 123 patients ... Read more

April 5, 2017April 5, 2017

Review Updates Different Treatment Strategies for Rheumatoid Arthritis

News, rheumatoid arthritis

A new literature review updated the information on the effectiveness and safety of different classes of treatment strategies for rheumatoid arthritis (RA). The study, “Efficacy of glucocorticoids, conventional and targeted ... Read more

April 3, 2017April 3, 2017

Moderate Alcohol Consumption in RA Patients Taking Methotrexate May Not Be So Dangerous, Study Suggests

News, rheumatoid arthritis

Moderate weekly alcohol consumption in rheumatoid arthritis (RA) patients who take methotrexate (MTX) therapy may not be as dangerous as previously suggested, according to new research. The study, “Quantifying the ... Read more

March 31, 2017March 31, 2017

European Commission Approves Xeljanz to Treat Moderate to Severe Rheumatoid Arthritis

News, rheumatoid arthritis

Doctors in the European Union’s 28 member countries may now prescribe Pfizer’s Xeljanz (tofacitinib citrate) to treat adults with moderate to severe active rheumatoid arthritis (RA). The European Commission (EC) ... Read more

March 29, 2017March 29, 2017

Europe OKs Amgevita for Treating Rheumatoid Arthritis and Other Inflammatory Diseases

News, rheumatoid arthritis

Amgen’s Amgevita, a biosimilar to AbbVie’s Humira (adalimumab), has received European Union approval for treating rheumatoid arthritis (RA) and other inflammatory diseases. The U.S. Food and Drug Administration approved the medicine, under the name ... Read more

March 27, 2017March 27, 2017

Antibodies Against Collagen II Protein May Predict Good Prognosis in RA Patients

News, rheumatoid arthritis

Antibodies against a protein called collagen II may be associated with a good prognosis in patients with rheumatoid arthritis (RA), according to the results of a recent study. The study, ... Read more

March 24, 2017March 24, 2017

Pregnant Women on High-dose Steroids at Higher Risk of Developing Infection, Study Shows

News

Pregnant women taking high doses of steroids for their autoimmune inflammatory diseases are at higher risk of developing a serious infection than those on lower steroid doses, according to a study. ... Read more

March 22, 2017March 22, 2017

Low RA Disease Activity Seen for 3 Years After Humira Stopped in Many Patients, Trial Shows

News, rheumatoid arthritis

Results from a clinical trial revealed that patients with early rheumatoid arthritis (RA) who stopped taking Humira (adalimumab) once their RA was under control maintained a low disease activity for up to three ... Read more

March 20, 2017March 20, 2017

UCB Targets Rheumatoid Arthritis Patients in ‘Wellness 4U’ Program

News, rheumatoid arthritis

Rheumatoid arthritis (RA) patients are known to be at higher risk for cardiovascular and muscle problems. In this context, Belgian pharmaceutical giant UCB has developed the Wellness 4U health and wellness program to encourage ... Read more

March 17, 2017March 17, 2017

EULAR Recommends Use of JAK Inhibitors, Including Xeljanz, for RA Management

News, rheumatoid arthritis

The European League Against Rheumatism (EULAR) has recommended the use of janus kinase (JAK) protein inhibitors, such as Pfizer’s Xeljanz (tofacitinib citrate), for the management of rheumatoid arthritis (RA). EULAR’s recommendations ... Read more